Form 4: Entrada Therapeutics President & COO Nathan Dowden Reports Sale of Shares

Nathan Dowden, President & COO of Entrada Therapeutics, sold 847 shares of common stock at $16 per share on September 26, 2024, according to a Form 4 filing.

Summary

• On September 26, 2024, Nathan J Dowden, President & COO of Entrada Therapeutics, Inc. (TRDA), reported a transaction involving the sale of 847 shares of common stock.
• The shares were sold at a price of $16 per share.
• Following the transaction, Dowden directly owns 125,149 shares of Entrada Therapeutics common stock.
• The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 8, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The filing simply reports a sale of shares under a pre-existing 10b5-1 plan, which doesn't necessarily indicate a positive or negative outlook.

Industry Context

Form 4 filings are standard disclosures required by the SEC when corporate insiders (officers, directors, or those holding more than 10% of a company's shares) buy or sell their company's stock. These filings are closely watched by investors for insights into management's perspective on the company's valuation and future prospects. However, sales under 10b5-1 plans are less informative because they are pre-scheduled.

Stakeholder Impact

• The sale of shares by a company executive could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates